Leishmania parasite membrane and phospholipid metabolism

The Leishmania parasite membrane and phospholipid metabolism encompass the biochemical pathways responsible for maintaining the structural integrity and signaling functions of the parasite's cellular envelope (Teixeira et al., 2016, PMID: 27103495). These pathways are distinct from mammalian systems, often utilizing unique lipids such as ergosterol and specialized ether-phospholipids that are vital for the parasite's survival within host macrophages (Roberts et al., 2003, PMID: 12668571). Therapeutic agents like Miltefosine exploit these differences by inhibiting key enzymes in the phospholipid biosynthetic pathway, such as CTP:phosphocholine cytidylyltransferase, or by directly perturbing the membrane's physical properties (Dorlo et al., 2012, PMID: 22543306). Disruption of these processes leads to a cascade of effects, including altered membrane permeability, inhibition of nutrient transport, and the induction of programmed cell death. This target area is central to the treatment of visceral and cutaneous leishmaniasis, providing a mechanism for selective toxicity against the protozoan. However, the complexity of lipid remodeling in different life stages of the parasite presents a challenge for drug efficacy and the prevention of resistance. Overall, the membrane and its metabolic enzymes remain a primary focus for developing new antileishmanial therapies due to their essentiality and divergence from human biology.

Other names

Leishmanial phospholipid biosynthetic pathwayLeishmania cell membrane metabolismLeishmania lipid metabolismLeishmania sterol and phospholipid biosynthesis

Inhibition of CTP:phosphocholine cytidylyltransferase, binding to membrane ergosterol to form aqueous pores, and interference with sphingolipid and glycosylphosphatidylinositol (GPI) anchor biosynthesis.